Scholarlink

Purpose <p>The Surveillance, Epidemiology, and End Results (SEER) program is a robust resource for U.S. cancer surveillance, capturing cancer patient data on diagnosis, treatment, survival, and demographics across diverse population-based cancer registries. The linkage of SEER data with Medicare and, more recently, Medicaid, enhances its utility for understanding treatment access, quality, and outcomes, as well as health policy impacts, on patients with brain tumors. This review describes the SEER-Medicaid and SEER-Medicare data resources and provides practical guidance for researchers to support robust epidemiologic and policy-relevant neuro-oncology investigations.</p> Methods <p>We conducted a narrative review of SEER-Medicaid and SEER-Medicare resources, summarizing data structures, linkage mechanisms, data availability, application process, potential uses for neuro-oncology research with examples, strengths and limitations for research, and future directions.</p> Results <p>Both SEER-Medicaid and SEER-Medicare offer rich opportunities to study access to care, treatment patterns, service utilization, and outcomes in brain tumor populations. However, the use of these data sources for neuro-oncology studies is limited to date.</p> Conclusions <p>SEER-Medicaid and SEER-Medicare are valuable yet underused resources in neuro-oncology. These databases enable a broader set of questions across the brain tumor care continuum, particularly for low-income and older patients, with relevance for addressing equity and improving outcomes in neuro-oncology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SEER-Medicaid and SEER-Medicare data for neuro-oncology research

  • 期刊论文

  • 发表日期：

    2026年2月10日

查看全文
  • Kimberly J. Johnson,
  • Derek S. Brown,
  • Kenton J. Johnston

摘要

Purpose

The Surveillance, Epidemiology, and End Results (SEER) program is a robust resource for U.S. cancer surveillance, capturing cancer patient data on diagnosis, treatment, survival, and demographics across diverse population-based cancer registries. The linkage of SEER data with Medicare and, more recently, Medicaid, enhances its utility for understanding treatment access, quality, and outcomes, as well as health policy impacts, on patients with brain tumors. This review describes the SEER-Medicaid and SEER-Medicare data resources and provides practical guidance for researchers to support robust epidemiologic and policy-relevant neuro-oncology investigations.

Methods

We conducted a narrative review of SEER-Medicaid and SEER-Medicare resources, summarizing data structures, linkage mechanisms, data availability, application process, potential uses for neuro-oncology research with examples, strengths and limitations for research, and future directions.

Results

Both SEER-Medicaid and SEER-Medicare offer rich opportunities to study access to care, treatment patterns, service utilization, and outcomes in brain tumor populations. However, the use of these data sources for neuro-oncology studies is limited to date.

Conclusions

SEER-Medicaid and SEER-Medicare are valuable yet underused resources in neuro-oncology. These databases enable a broader set of questions across the brain tumor care continuum, particularly for low-income and older patients, with relevance for addressing equity and improving outcomes in neuro-oncology.